Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 23, 2004. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and updates regarding Director interests in the US Retirement Savings Plan.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Date: August 20, 2004.
- Purchase Price: 1,074.58 pence per share.
- Treasury Holdings Post-Purchase: 36,618,000 shares.
- Shares in Issue (excluding Treasury): 5,897,464,701 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 500,000 shares for Treasury. Additionally, a re-valuation of the cash element within the US Retirement Savings Plan resulted in an increase in the notional allocation of Ordinary Share ADRs for specific directors on August 5, 2004, at a price of $40.18 per share.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase against the stated price of 1,074.58 pence.
- Confirm the updated total share count (5,897,464,701 in issue) in subsequent filings.
- Review the specific notional ADR allocation increases for Directors Dr. J.P. Garnier (47 units) and Dr. T. Yamada (16 units) as reported.
- Note that this filing does not contain quarterly or annual financial performance data.